ahlam1399
03-21-2016, 03:44 PM
BioMarin drug for genetic disorder succeeds in late-stage study
March 21 (Reuters) - BioMarin Pharmaceutical Inc said preliminary data showed its experimental drug met the main goal of reducing blood phenylalanine in patients with a genetic disorder, in a late-stage study.
http://i0.wp.com/reuters.us.feedsportal.com/c/35217/f/654213/s/4e67ce9f/sc/14/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=fm1e_iA8l7M:8oFi54jThd8:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=fm1e_iA8l7M:8oFi54jThd8:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=fm1e_iA8l7M:8oFi54jThd8:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=fm1e_iA8l7M:8oFi54jThd8:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=fm1e_iA8l7M:8oFi54jThd8:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/fm1e_iA8l7M
March 21 (Reuters) - BioMarin Pharmaceutical Inc said preliminary data showed its experimental drug met the main goal of reducing blood phenylalanine in patients with a genetic disorder, in a late-stage study.
http://i0.wp.com/reuters.us.feedsportal.com/c/35217/f/654213/s/4e67ce9f/sc/14/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=fm1e_iA8l7M:8oFi54jThd8:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=fm1e_iA8l7M:8oFi54jThd8:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=fm1e_iA8l7M:8oFi54jThd8:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=fm1e_iA8l7M:8oFi54jThd8:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=fm1e_iA8l7M:8oFi54jThd8:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/fm1e_iA8l7M